Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pieper - CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Oren Livnat - H.C. Wainwright Glen Santangelo - Jefferies David Amsellem - Piper Sandler Leland Gershell - Oppenheimer Mazahir Alimohamed - Leerink Partners Operator Good morning, and welcome to the Xeris Biopharma Fourth Quarter and Full Year 2024 Financial Results.
Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Xeris Biopharma (XERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.10 per share a year ago.
Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation CHICAGO and ARLINGTON, Va. , Jan. 21, 2025 /PRNewswire/ -- The American Diabetes Association® (ADA) and Xeris Pharmaceuticals® (Xeris BioPharma Holdings, Inc.), a national supporter of the ADA, are pleased to announce a multi-year strategic partnership to reinforce the importance of prescribing glucagon, preferably ready-to-use, for all individuals with diabetes who are treated with insulin and/or insulin secretagogues or those at high risk of hypoglycemia (low blood glucose, also called low blood sugar), in line with the ADA's recently updated Standards of Care in Diabetes—2025 (Standards of Care).1 "Severe hypoglycemia is life-threatening, and people with diabetes on blood glucose-lowering medication are at risk for hypoglycemia.
Xeris Biopharma Holdings, Inc. is an overlooked specialty pharmaceutical company with three FDA-approved products, utilizing its proprietary XeriSol and XeriJect technologies to develop innovative injectable drug formulations. Gvoke and Recorlev drive Xeris' rapid growth, with Gvoke holding 34% of the retail glucagon market and Recorlev expanding its patient base by 124%. Xeris' strategic partnerships and promising pipeline, particularly XP-8121 for hypothyroidism, offer strong potential for value creation and long-term growth.
Xeris Biopharma is trading above my Buy Threshold of $2.76 and is nearing a potential breakout above the $3.25 resistance level. The company shows strong revenue growth, driven by products like Gvoke and Recorlev, despite not yet reporting a positive EPS. Risks include intense competition and potential need for additional funding, but projected revenue growth suggests significant upside potential.
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2024, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 364,000 shares of its common stock to 42 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Eq.
Xeris Biopharma (XERS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.14 per share a year ago.
From a technical perspective, Xeris Biopharma Holdings, Inc. (XERS) is looking like an interesting pick, as it just reached a key level of support. XERS's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Xeris Biopharma Holdings (NASDAQ:XERS) announced a CEO succession plan with John Shannon taking over from Paul Edick on August 1, 2024. Edick, the current CEO and chairman, will retire from his roles after more than seven years with the company.